TX-FLUENCE-BY-OSRAM
23.11.2021 13:32:12 CET | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today it has partnered with White Lion Holdings , the leading consultant providing complete solutions for new and aspiring cannabis growers in South Africa.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211123005520/en/
Fluence’s South African partners include local distributor The Lamphouse, the largest supplier of specialized lamps in Africa with more than 40 years of experience in numerous specialty lighting sectors, and White Lion Holdings, a company offering complete cannabis growing solutions and consultancy, led by CEO Cornel van der Watt. Van der Watt has served at the forefront of developing cannabis markets in the U.S., Canada, the Netherlands and Lesotho, and has consulted extensively in Australia.
“Local partnerships are a key factor in delivering fast and reliable solutions to growers. Our stellar partners know the choice of lighting supplier is crucial to delivering consistent, high-quality yields premium clients in the northern hemisphere require,” said Timo Bongartz, Fluence’s general manager for Europe, the Middle East and Africa (EMEA). “Van der Watt chose to partner with Fluence and our local partner The Lamphouse based on his experience with Fluence’s superior LED products and valuable support in various jurisdictions where he has historically consulted cannabis growers.”
According to Prohibition Partners’ African Cannabis Report™ , by 2023, Africa’s legal cannabis industry could be worth more than $7.1 billion annually, with South Africa alone contributing an estimated $1.7 billion per year. The South African government’s recognition of the industry as a key to economic revival mirrors Prohibition Partners’ assessment—the cannabis industry represents the potential to create between 10,000 -25,000 job opportunities in a country with the highest unemployment rate in the world.
“The African cannabis market holds incredible potential and we know we’ve found the right partner in White Lion Holdings. We’re proud to collaborate with such a trusted brand and to support the growers who are revolutionizing the South African cannabis market,” Bongartz continues.
As the cannabis industry continues to gain traction throughout the country and continent, White Lion Holdings suggests growers will not only need innovative technology at their fingertips, but evidence-backed cultivation practices that yield high-quality crops, improved yields and consistent growth patterns.
“We’re thrilled to partner with Fluence and its local partner The Lamphouse,” said Van der Watt, who is currently consulting and managing four commercial operations throughout South Africa with other operations in the pipeline. “The cannabis plant is highly photosensitive. We prefer natural lighting and South Africa has an advantage in this regard with ample, good quality natural light. By choosing the location of the greenhouse well, one can get up to 11 hours of natural light for free. Then, we integrate supplemental lighting into the facility to optimize crop yield.”
The South African market is still in its infancy. Through its partnership with White Lion Holdings, Fluence lighting solutions have been implemented at pre-licensed and licensed cannabis greenhouse and indoor facilities throughout the country.
“I am testing various lighting solutions all the time, but those tests only reaffirm my partnership with Fluence and its local partner The Lamphouse given each company’s superior quality and valuable support. Thanks to consistent lighting, I have been able to surpass production targets. That is only possible with superior lighting,” Van der Watt added.
To achieve longevity in an industry that can quickly become crowded with new technologies and cultivation solutions, investors and growers must ensure they partner with experts in their respective fields who are purpose-built to support cultivators for the long-term.
“The Fluence system all but eliminates lighting as a variable and delivers a high return on investment. Optimizing the correct lighting strategy for the correct application and layout is one of the critical components to successful crop,” said Glenn Morris, CEO of The Lamphouse.
For more information on Fluence, visit www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM, creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit www.fluence.science .
About Cornel van der Watt and White Lion Holdings
With over 29 years of international, large scale cannabis cultivation experience under his belt, the White Lion Cornel van der Watt is in a class of his own. His knowledge of all aspects of the cannabis industry and his connections in the global cannabis community are unparalleled. He has also been at the forefront of the cannabis movement in South Africa since inception.
Every path he has walked in his professional and personal life has led him back to the cannabis industry. This path traces back to his qualification in chemical engineering, experience in scientific glassblowing, expertise in cultivation abroad and locally, studies in tissue cultivation, cloning and genetics, his community upliftment work as well as training and consulting.
While Cornel has become a scientist, a geneticist, a businessman and Cannabis Supremo, at the heart of his consultancy lies a deep and spiritual connection with the cannabis plant. For more information about White Lion Holding, visit https://www.whitelionholdings.co.za .
About The Lamphouse
Established in 1976, The Lamphouse is the largest supplier and distributor of specialized lamps in Southern Africa. Over the past 40 years, The Lamphouse has developed strategic relationships with suppliers and customers alike, providing lighting applications for horticulture, medical solutions, stage and studio, airfield, navigation and more. The company is headquartered in Johannesburg, South Africa, with additional offices in Cape Town and Durban. For more information about The Lamphouse, visit https://www.thelamphouse.co.za .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005520/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
